COFCO Health (01610.HK) released its interim performance, with a profit of 198 million yuan attributable to shareholders before adjustments for fair value of biological assets, turning a loss into a profit year-on-year.

Wisdom Financial News App reported that COFCO Jiajia Kang (01610.HK) released its mid-term performance for 2025. After the fair value adjustment of biological assets, the group achieved a revenue of 8.963 billion yuan (same unit below), an increase of 19.77% year-on-year. The net profit attributable to the company's owners was 317 million yuan, an increase of 0.2% year-on-year. Basic earnings per share were 0.0691 yuan.